KOBV Portal

Hits per page

hits 1 - 10 | 30 hits

Sorting

Online Resource

Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function

Galluzzo, Vincenzo ; Zazzara, Maria Beatrice ; Ciciarello, Francesca ; [et al.]

Elsevier BV ; 2022

In: Clinical Nutrition ESPEN Vol. 51 ( 2022-10), p. 215-221

add to watchlist on the watchlist

Details

In: Clinical Nutrition ESPEN, Elsevier BV, Vol. 51 ( 2022-10), p. 215-221

Type of Medium: Online Resource

ISSN: 2405-4577

URL: Article

DOI: 10.1016/j.clnesp.2022.08.029

Language: English

Publisher: Elsevier BV

Publication Date: 2022

detail.hit.zdb_id: 2816659-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Malnutrition in COVID-19 survivors: prevalence and risk factors

Tosato, Matteo ; Calvani, Riccardo ; Ciciarello, Francesca ; [et al.]

Springer Science and Business Media LLC ; 2023

In: Aging Clinical and Experimental Research Vol. 35, No. 10 ( 2023-09-04), p. 2257-2265

add to watchlist on the watchlist

Details

In: Aging Clinical and Experimental Research, Springer Science and Business Media LLC, Vol. 35, No. 10 ( 2023-09-04), p. 2257-2265

Abstract: Nutritional status is a critical factor throughout COVID-19 disease course. Malnutrition is associated with poor outcomes in hospitalized COVID-19 patients. Aim To assess the prevalence of malnutrition and identify its associated factors in COVID-19 survivors. Methods Study cohort included 1230 COVID-19 survivors aged 18–86 attending a post-COVID-19 outpatient service. Data on clinical parameters, anthropometry, acute COVID-19 symptoms, lifestyle habits were collected through a comprehensive medical assessment. Malnutrition was assessed according to Global Leadership Initiative on Malnutrition (GLIM) criteria. Results Prevalence of malnutrition was 22% at 4–5 months after acute disease. Participants who were not hospitalized during acute COVID-19 showed a higher frequency of malnutrition compared to those who needed hospitalization (26% versus 19%, p 〈 0.01). Malnutrition was found in 25% COVID-19 survivors over 65 years of age compared to 21% younger participants (p 〈 0.01). After multivariable adjustment, the likelihood of being malnourished increased progressively and independently with advancing age (Odds ratio [OR] 1.02; 95% CI 1.01–1.03) and in male participants (OR 5.56; 95% CI 3.53–8.74). Malnutrition was associated with loss of appetite (OR 2.50; 95% CI 1.73–3.62), and dysgeusia (OR 4.05; 95% CI 2.30–7.21) during acute COVID-19. Discussion In the present investigation we showed that malnutrition was highly prevalent in a large cohort of COVID-19 survivors at 4–5 months from acute illness. Conclusions Our findings highlight the need to implement comprehensive nutritional assessment and therapy as an integral part of care for COVID-19 patients.

Type of Medium: Online Resource

ISSN: 1720-8319

URL: Article

DOI: 10.1007/s40520-023-02526-4

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2023

detail.hit.zdb_id: 2119282-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Maintenance chemotherapy with pemetrexed in epiteliomorfe malignant pleural mesothelioma.

Nacci, Angelo ; Lotesoriere, Claudio ; Montrone, Michele ; [et al.]

American Society of Clinical Oncology (ASCO) ; 2013

In: Journal of Clinical Oncology Vol. 31, No. 15_suppl ( 2013-05-20), p. e18545-e18545

add to watchlist on the watchlist

Details

In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e18545-e18545

Abstract: e18545 Background: Maintenance chemotherapy with pemetrexed is not the standard treatment of choice in patients with locally advanced or metastatic epiteliomorfe malignant pleural mesothelioma (EMPM). We would assess the safety and efficacy of a treatment with pemetrexed until progression disease after 4 or 6 cycles of induction therapy with or without platin. Methods: From July 2008 to September 2012, 21 patients (18 males and 3 females with a median age of 67 years range 58-84) with locally advanced or metastatic epiteliomorfe malignant pleural mesothelioma (EMPM) were enrolled. In all patients histology was epiteliomorfe malignant mesothelioma. Only 15 patients (71,4%) had a PS 0 whereas 6 (28,6%) had a PS 1. All patients received an induction therapy with or without platin. Each patient received an average of 5,6 cycles of induction chemotherapy. Then all patients received a maintenance chemotherapy with pemetrexed 500 mg/mq intavenously over 10 minutes every 3 weeks. Each patient received an average of 7,3 cycles of maintenance chemotherapy. All patients received folic acid and vitamin B12 supplementation to improve safety. Results: At the time of analysis all patients were evaluable for response. Fourteen patients (66,6 %) had a partial response and two of these underwent surgery and obtained a complete response. Six patients (28,5%) had a stable disease. The median overall survival was 13 months, while median progression-free survival was 11 months. Grade 2-3 of WHO haematological toxicities (anemia and neutropenia) occurred in 4 patient (19%). We also observed grade 2-3 of WHO gastrointestinal toxicities (diarrhea, nausea and vomiting) in 2 patient (9.5%). Grade 2 of lack of appetite and asthenia occurred in 3 patients (14.3%). Conclusions: Our data show that a maintenance chemotherapy with pemetrexed in EMPM resulted in a moderate overall survival (13 months). These results indicate that patients with EMPM could benefit from a maintenance treatment with pemetrexed.

Type of Medium: Online Resource

ISSN: 0732-183X , 1527-7755

URL: Article

DOI: 10.1200/jco.2013.31.15_suppl.e18545

RVK:

XA 52760

RVK:

XA 10000

Language: English

Publisher: American Society of Clinical Oncology (ASCO)

Publication Date: 2013

detail.hit.zdb_id: 2005181-5

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment

Orlando, Laura ; Schiavone, Paola ; Fedele, Palma ; [et al.]

Informa UK Limited ; 2012

In: Expert Opinion on Therapeutic Targets Vol. 16, No. sup2 ( 2012-04), p. S83-S89

add to watchlist on the watchlist

Details

In: Expert Opinion on Therapeutic Targets, Informa UK Limited, Vol. 16, No. sup2 ( 2012-04), p. S83-S89

Type of Medium: Online Resource

ISSN: 1472-8222 , 1744-7631

URL: Article

DOI: 10.1517/14728222.2011.648925

Language: English

Publisher: Informa UK Limited

Publication Date: 2012

detail.hit.zdb_id: 2028202-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

A malaria parasite phospholipase facilitates efficient asexual blood stage egress

Ramaprasad, Abhinay ; Burda, Paul-Christian ; Koussis, Konstantinos ; [et al.]

Public Library of Science (PLoS) ; 2023

In: PLOS Pathogens Vol. 19, No. 6 ( 2023-6-23), p. e1011449-

add to watchlist on the watchlist

Details

In: PLOS Pathogens, Public Library of Science (PLoS), Vol. 19, No. 6 ( 2023-6-23), p. e1011449-

Abstract: Malaria parasite release (egress) from host red blood cells involves parasite-mediated membrane poration and rupture, thought to involve membrane-lytic effector molecules such as perforin-like proteins and/or phospholipases. With the aim of identifying these effectors, we disrupted the expression of two Plasmodium falciparum perforin-like proteins simultaneously and showed that they have no essential roles during blood stage egress. Proteomic profiling of parasite proteins discharged into the parasitophorous vacuole (PV) just prior to egress detected the presence in the PV of a lecithin:cholesterol acyltransferase (LCAT; PF3D7_0629300). Conditional ablation of LCAT resulted in abnormal egress and a reduced replication rate. Lipidomic profiles of LCAT-null parasites showed drastic changes in several phosphatidylserine and acylphosphatidylglycerol species during egress. We thus show that, in addition to its previously demonstrated role in liver stage merozoite egress, LCAT is required to facilitate efficient egress in asexual blood stage malaria parasites.

Type of Medium: Online Resource

ISSN: 1553-7374

URL: Article

DOI: 10.1371/journal.ppat.1011449

DOI: 10.1371/journal.ppat.1011449.g001

DOI: 10.1371/journal.ppat.1011449.g002

DOI: 10.1371/journal.ppat.1011449.g003

DOI: 10.1371/journal.ppat.1011449.g004

DOI: 10.1371/journal.ppat.1011449.g005

DOI: 10.1371/journal.ppat.1011449.g006

DOI: 10.1371/journal.ppat.1011449.s001

DOI: 10.1371/journal.ppat.1011449.s002

DOI: 10.1371/journal.ppat.1011449.s003

DOI: 10.1371/journal.ppat.1011449.s004

DOI: 10.1371/journal.ppat.1011449.s005

DOI: 10.1371/journal.ppat.1011449.s006

DOI: 10.1371/journal.ppat.1011449.s007

DOI: 10.1371/journal.ppat.1011449.s008

DOI: 10.1371/journal.ppat.1011449.s009

DOI: 10.1371/journal.ppat.1011449.s010

DOI: 10.1371/journal.ppat.1011449.s011

DOI: 10.1371/journal.ppat.1011449.s012

DOI: 10.1371/journal.ppat.1011449.s013

DOI: 10.1371/journal.ppat.1011449.r001

DOI: 10.1371/journal.ppat.1011449.r002

DOI: 10.1371/journal.ppat.1011449.r003

DOI: 10.1371/journal.ppat.1011449.r004

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2023

detail.hit.zdb_id: 2205412-1

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

COVID-19 atypical Parsonage-Turner syndrome: a case report

Zazzara, Maria Beatrice ; Modoni, Anna ; Bizzarro, Alessandra ; [et al.]

Springer Science and Business Media LLC ; 2022

In: BMC Neurology Vol. 22, No. 1 ( 2022-12)

add to watchlist on the watchlist

Details

In: BMC Neurology, Springer Science and Business Media LLC, Vol. 22, No. 1 ( 2022-12)

Abstract: Neurological manifestations of Sars-CoV-2 infection have been described since March 2020 and include both central and peripheral nervous system manifestations. Neurological symptoms, such as headache or persistent loss of smell and taste, have also been documented in COVID-19 long-haulers. Moreover, long lasting fatigue, mild cognitive impairment and sleep disorders appear to be frequent long term neurological manifestations after hospitalization due to COVID-19. Less is known in relation to peripheral nerve injury related to Sars-CoV-2 infection. Case presentation We report the case of a 47-year-old female presenting with a unilateral chest pain radiating to the left arm lasting for more than two months after recovery from Sars-CoV-2 infection. After referral to our post-acute outpatient service for COVID-19 long haulers, she was diagnosed with a unilateral, atypical, pure sensory brachial plexus neuritis potentially related to COVID-19, which occurred during the acute phase of a mild Sars-CoV-2 infection and persisted for months after resolution of the infection. Conclusions We presented a case of atypical Parsonage-Turner syndrome potentially triggered by Sars-CoV-2 infection, with symptoms and repercussion lasting after viral clearance. A direct involvement of the virus remains uncertain, and the physiopathology is unclear. The treatment of COVID-19 and its long-term consequences represents a relatively new challenge for clinicians and health care providers. A multidisciplinary approach to following-up COVID-19 survivors is strongly advised.

Type of Medium: Online Resource

ISSN: 1471-2377

URL: Article

DOI: 10.1186/s12883-022-02622-4

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2022

detail.hit.zdb_id: 2041347-6

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Residual respiratory impairment after COVID-19 pneumonia

Lombardi, Francesco ; Calabrese, Angelo ; Iovene, Bruno ; [et al.]

Springer Science and Business Media LLC ; 2021

In: BMC Pulmonary Medicine Vol. 21, No. 1 ( 2021-12)

add to watchlist on the watchlist

Details

In: BMC Pulmonary Medicine, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2021-12)

Abstract: The novel coronavirus SARS-Cov-2 can infect the respiratory tract causing a spectrum of disease varying from mild to fatal pneumonia, and known as COVID-19. Ongoing clinical research is assessing the potential for long-term respiratory sequelae in these patients. We assessed the respiratory function in a cohort of patients after recovering from SARS-Cov-2 infection, stratified according to PaO 2 /FiO 2 (p/F) values. Method Approximately one month after hospital discharge, 86 COVID-19 patients underwent physical examination, arterial blood gas (ABG) analysis, pulmonary function tests (PFTs), and six-minute walk test (6MWT). Patients were also asked to quantify the severity of dyspnoea and cough before, during, and after hospitalization using a visual analogic scale (VAS). Seventy-six subjects with ABG during hospitalization were stratified in three groups according to their worst p/F values: above 300 (n = 38), between 200 and 300 (n = 30) and below 200 (n = 20). Results On PFTs, lung volumes were overall preserved yet, mean percent predicted residual volume was slightly reduced (74.8 ± 18.1%). Percent predicted diffusing capacity for carbon monoxide (DLCO) was also mildly reduced (77.2 ± 16.5%). Patients reported residual breathlessness at the time of the visit (VAS 19.8, p 〈 0.001). Patients with p/F below 200 during hospitalization had lower percent predicted forced vital capacity (p = 0.005), lower percent predicted total lung capacity (p = 0.012), lower DLCO (p 〈 0.001) and shorter 6MWT distance (p = 0.004) than patients with higher p/F. Conclusion Approximately one month after hospital discharge, patients with COVID-19 can have residual respiratory impairment, including lower exercise tolerance. The extent of this impairment seems to correlate with the severity of respiratory failure during hospitalization.

Type of Medium: Online Resource

ISSN: 1471-2466

URL: Article

DOI: 10.1186/s12890-021-01594-4

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2021

detail.hit.zdb_id: 2059871-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Manageable treatment with lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): Efficacy and safety data.

Orlando, Laura ; Lutrino, Stefania Eufemia ; Fontanella, Caterina ; [et al.]

American Society of Clinical Oncology (ASCO) ; 2015

In: Journal of Clinical Oncology Vol. 33, No. 15_suppl ( 2015-05-20), p. e11571-e11571

add to watchlist on the watchlist

Details

In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 33, No. 15_suppl ( 2015-05-20), p. e11571-e11571

Type of Medium: Online Resource

ISSN: 0732-183X , 1527-7755

URL: Article

DOI: 10.1200/jco.2015.33.15_suppl.e11571

RVK:

XA 52760

RVK:

XA 10000

Language: English

Publisher: American Society of Clinical Oncology (ASCO)

Publication Date: 2015

detail.hit.zdb_id: 2005181-5

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Author response image 1. Stability of SeMeCo colony over time. : Starting from a SeMeCo micro-colony on minimal media, a giant colony was established and composition was followed by replica plating for 90 generations. Biomass gain is calculated starting from the single cell.

Campbell, Kate ; Vowinckel, Jakob ; Mülleder, Michael ; [et al.]

eLife Sciences Publications, Ltd ; 2015

In: eLife Vol. 4 ( 2015-10-26)

add to watchlist on the watchlist

Details

In: eLife, eLife Sciences Publications, Ltd, Vol. 4 ( 2015-10-26)

Abstract: Life is sustained by an array of chemical reactions that is collectively referred to as metabolism. Some of these reactions break down complex substances to release energy and vital compounds, while others make new molecules from smaller building blocks. Bacterial communities are regularly composed of heterogeneous species, several of which have lost one or more essential metabolic pathways. Nevertheless, these cells can still survive by making use of metabolic products released by their neighbouring cells. Yeast are single-celled fungi that also form colonies and, as eukaryotes, they possess cells that are more similar to our own. However, in the laboratory, complementary metabolically deficient yeast cells do not survive when mixed together. It was presumed this is because yeast cells make only enough of each essential metabolite for themself, and so can’t replace those that are missing from their neighbouring cells. Campbell et al. now challenge this view by finding that yeast cells release a variety of metabolites, they use these released metabolites in preference to making their own, and possess the capacity to grow on the basis of a non-cell-autonomous metabolism. This discovery came with the design of a new experimental test to study metabolite exchange interactions. This method uses yeast cells that have one or more of their own metabolic genes disabled, and instead have a copy of these genes on small circular DNA 'mini-chromosomes' (called plasmids). The gene on the plasmid can compensate for the yeast having its own gene missing, and allows the cell to still make the metabolic product it needs to survive. However, as a single cell divides to form a colony, cells randomly lose these plasmids, leaving some of the cells deficient for a particular metabolite. These cells can only survive if the other cells in the colony export the missing metabolite in the quantity needed for growth. Using this test, Campbell et al. found that yeast cells can export missing metabolites at levels needed to sustain these emerging metabolic mutants. Additionally, these yeast communities could grow at levels comparable to other yeast without metabolic deficiencies. The resulting colonies also feature one of several different genetic and metabolic profiles, which change in response to the metabolite that is missing. These findings demonstrate that yeast cells can exchange high amounts of metabolites, sufficient to form cooperative colonies, and as metabolite concentrations are not altered compared to normal cells, it is likely that exchange of metabolites is ongoing between neighbours in yeast communities. The additional discovery that yeast stop making metabolites when they can obtain them from neighbouring cells has implications for research. This is because many yeast genetic studies use metabolically deficient strains that are supplemented in culture with metabolites. Future work could address whether such supplementation has kept certain functions of metabolism hidden.

Type of Medium: Online Resource

ISSN: 2050-084X

URL: Article

DOI: 10.7554/eLife.09943

DOI: 10.7554/eLife.09943.001

DOI: 10.7554/eLife.09943.002

DOI: 10.7554/eLife.09943.003

DOI: 10.7554/eLife.09943.004

DOI: 10.7554/eLife.09943.005

DOI: 10.7554/eLife.09943.006

DOI: 10.7554/eLife.09943.007

DOI: 10.7554/eLife.09943.008

DOI: 10.7554/eLife.09943.009

DOI: 10.7554/eLife.09943.010

DOI: 10.7554/eLife.09943.011

DOI: 10.7554/eLife.09943.012

DOI: 10.7554/eLife.09943.013

DOI: 10.7554/eLife.09943.014

DOI: 10.7554/eLife.09943.015

DOI: 10.7554/eLife.09943.016

DOI: 10.7554/eLife.09943.017

DOI: 10.7554/eLife.09943.018

DOI: 10.7554/eLife.09943.019

DOI: 10.7554/eLife.09943.020

DOI: 10.7554/eLife.09943.021

DOI: 10.7554/eLife.09943.022

DOI: 10.7554/eLife.09943.023

DOI: 10.7554/eLife.09943.025

DOI: 10.7554/eLife.09943.026

DOI: 10.7554/eLife.09943.024

Language: English

Publisher: eLife Sciences Publications, Ltd

Publication Date: 2015

detail.hit.zdb_id: 2687154-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience.

Marino, Antonella ; Caliolo, Chiara ; Sponziello, Francesco ; [et al.]

American Society of Clinical Oncology (ASCO) ; 2013

In: Journal of Clinical Oncology Vol. 31, No. 15_suppl ( 2013-05-20), p. e14605-e14605

add to watchlist on the watchlist

Details

In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e14605-e14605

Abstract: e14605 Background: Cetuximab and panitumumab are monoclonal antibodies that target EGFR, approved for the treatment of KRAS WT MCRC. Few data describe the activity of panitumumabafter cetuximab-irinotecan based regimen failure. Methods: The aim of this study is to assess if panitumumab has some activity in pts with KRAS WT MCRC that has progressed on prior cetuximab. Results: We retrospectively analysed 25 pts with KRAS WT MCRC who received from 07/2009 to 01/2013 panitumumab after progression on cetuximab. Median age: 63 yrs (40-78), primary site tumor: colon 64%, rectum 36%; synchronous metastases 36%, metachronous 64%. Sites of metastases: liver 44%, liver and lung 8%, other sites 48%. All pts had previously received cetuximab associated with irinotecan (20 pts) or oxaliplatin (5 pts) and subsequently received panitumumab. We withdrew cetuximab because of intolerance in 4 pts (16%), while 21 pts (84%) with ECOG PS 0-1 who had previously responded to cetuximab (ORR plus SD lasting more than 5 months) received panitumumab “off-label” after progression on cetuximab because strongly motivated to continue treatment. Median cycles of panitumumab were 7 (1-54). Only eighteen pts were evaluable for ORR (4 pts received 1-2 cycles and then died, 3 pts too early). We observed one PR (5%); five pts (28%) had SD, median duration 9 months. Median PFS was 5 months (3-28) and median OS 8 months (5-41). All pts were evaluable for toxicity. No pts developed anemia, nor neutropenia. One patient (4%) developed grade 2 CTCAE version 4.03 thrombocytopenia. Eight pts (32%) developed grade 2-3 CTCAE version 4.03 dry skin or rash, 2 pts (8%) grade 2 CTCAE version 4.03 nausea-vomiting. Conclusions: Panitumumab has minimal benefit in pts with KRAS WT MCRC who have progressed on prior cetuximab andthis approach up to date should not be adopted in the clinical practice. Our data anyway show a longer PFS and OS as compared to other few series in the same setting. Further confirmatory prospective studies with larger series of pts would be necessary.

Type of Medium: Online Resource

ISSN: 0732-183X , 1527-7755

URL: Article

DOI: 10.1200/jco.2013.31.15_suppl.e14605

RVK:

XA 52760

RVK:

XA 10000

Language: English

Publisher: American Society of Clinical Oncology (ASCO)

Publication Date: 2013

detail.hit.zdb_id: 2005181-5

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

hits 1 - 10 | 30 hits

Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.

Kooperativer Bibliotheksverbund

Berlin Brandenburg